Section of Allergy & Immunology, Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands.
Laboratory of Medical Immunology, Department of Immunology, Erasmus MC, Rotterdam, Netherlands.
Front Immunol. 2021 Mar 15;12:625284. doi: 10.3389/fimmu.2021.625284. eCollection 2021.
The Mas-related G-protein-coupled receptor X2 (MRGPRX2) is prominently expressed by mast cells and induces degranulation upon binding by different ligands. Its activation has been linked to various mast cell-related diseases, such as chronic spontaneous urticaria, atopic dermatitis and asthma. Therefore, inhibition of MRGPRX2 activity represents a therapeutic target for these conditions. However, the exact pathophysiology of this receptor is still unknown. In vitro research with mast cells is often hampered by the technical limitations of available cell lines. The human mast cell types LAD2 and HuMC (human mast cells cultured from CD34+ progenitor cells) most closely resemble mature human mast cells, yet have a very slow growth rate. A fast proliferating alternative is the human mast cell line HMC1, but they are considered unsuitable for degranulation assays due to their immature phenotype. Moreover, the expression and functionality of MRGPRX2 on HMC1 is controversial. Here, we describe the MRGPRX2 expression and functionality in HMC1 cells, and compare these with LAD2 and HuMC. We also propose a model to render HMC1 suitable for degranulation assays by pre-incubating them with latrunculin-B (Lat-B). Expression of MRGPRX2 by HMC1 was proven by RQ-PCR and flowcytometry, although at lower levels compared with LAD2 and HuMC. Pre-incubation of HMC1 cells with Lat-B significantly increased the overall degranulation capacity, without significantly changing their MRGPRX2 expression, phenotype or morphology. The MRGPRX2 specific compound 48/80 (C48/80) effectively induced degranulation of HMC1 as measured by CD63 membrane expression and β-hexosaminidase release, albeit in lower levels than for LAD2 or HuMC. HMC1, LAD2 and HuMC each had different degranulation kinetics upon stimulation with C48/80. Incubation with the MRGPRX2 specific inhibitor QWF inhibited C48/80-induced degranulation, confirming the functionality of MRGPRX2 on HMC1. In conclusion, HMC1 cells have lower levels of MRGPRX2 expression than LAD2 or HuMC, but are attractive for research because of their high growth rate and stable phenotype. HMC1 can be used to study MRGPRX2-mediated degranulation after pre-incubation with Lat-B, which provides the opportunity to explore MPRGRX2 biology in mast cells in a feasible way.
Mas 相关 G 蛋白偶联受体 X2(MRGPRX2)主要由肥大细胞表达,在与不同配体结合后诱导脱颗粒。其激活与各种肥大细胞相关疾病有关,如慢性自发性荨麻疹、特应性皮炎和哮喘。因此,抑制 MRGPRX2 的活性是这些疾病的治疗靶点。然而,该受体的确切病理生理学仍不清楚。由于现有细胞系的技术限制,体外研究肥大细胞往往受到阻碍。LAD2 和 HuMC(从 CD34+祖细胞培养的人肥大细胞)是最接近成熟人肥大细胞的人类肥大细胞类型,但生长速度非常缓慢。一种快速增殖的替代方法是人类肥大细胞系 HMC1,但由于其不成熟的表型,它们被认为不适合脱颗粒测定。此外,HMC1 中 MRGPRX2 的表达和功能存在争议。在这里,我们描述了 HMC1 细胞中 MRGPRX2 的表达和功能,并将其与 LAD2 和 HuMC 进行了比较。我们还提出了一种通过预先孵育 latrunculin-B(Lat-B)使 HMC1 适合脱颗粒测定的模型。通过 RQ-PCR 和流式细胞术证明 HMC1 表达 MRGPRX2,尽管与 LAD2 和 HuMC 相比,表达水平较低。预先孵育 HMC1 细胞用 Lat-B 显著增加了整体脱颗粒能力,而不会显著改变其 MRGPRX2 的表达、表型或形态。MRGPRX2 特异性化合物 48/80(C48/80)有效诱导 HMC1 脱颗粒,通过 CD63 膜表达和β-己糖胺酶释放来衡量,尽管水平低于 LAD2 或 HuMC。HMC1、LAD2 和 HuMC 在受到 C48/80 刺激时的脱颗粒动力学各不相同。用 MRGPRX2 特异性抑制剂 QWF 孵育可抑制 C48/80 诱导的脱颗粒,证实 HMC1 上 MRGPRX2 的功能。总之,HMC1 细胞的 MRGPRX2 表达水平低于 LAD2 或 HuMC,但由于其生长速度快且表型稳定,因此适合研究。HMC1 可以在预先用 Lat-B 孵育后用于研究 MRGPRX2 介导的脱颗粒,这为以可行的方式探索肥大细胞中 MRGPRX2 生物学提供了机会。